Ironwood制药 IRWD 深 沪
等待开盘 11-06 09:30:00 美东时间
2.06
+0.190
+10.16%
华盛通- 最 高2.23
- 今 开1.88
- 成交量 405.14万股
- 最 低 1.875
- 昨 收 1.87
- 总市值 3.34亿
- 52周最高 5.1288
- 市盈率 静 374.55
- 换手率 2.50%
- 52周最低 0.5271
- 委 比 -65.14%
- 总股本 1.62亿
- 历史最高 18.915
- 量 比 1.93
- 振 幅 18.98%
- 历史最低 0.5271
- 每 手 1
- 风险率 1.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Approved Linzess Capsules For Pediatric Patients 7 Years And Older With Irritable Bowel Syndrome With Constipation; Linzess Recommended Dosage For Pediatric Patients 7 Years And Older With IBS-C Is 145 mcg Orally Once Daily
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-1st-drug-children-7-years-and-older-irritable-bowel-syndrome-constipation
今天 00:33
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alphatec Holdings (NASDAQ:ATEC) shares rose 21.7% to $19.88 during Fri...
10-31 20:10
Why American Eagle Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Shares of American Eagle Outfitters, Inc. (NYSE:AEO) rose sharply in pre-market...
09-04 17:42
Ironwood Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY25 sales guidance with its midpoint above estimates.
Ironwood Pharmaceuticals shares are trading higher after the company reported b...
08-07 22:47
Ironwood Pharmaceuticals Sees FY2025 Sales $260.000M-$290.000M vs $270.600M Est
Ironwood Pharmaceuticals (NASDAQ:IRWD) sees FY2025 sales of $260.000 million-$290.000 million vs $270.600 million analyst estimate.
08-07 19:25
Ironwood Pharmaceuticals Q2 Adj. EPS $0.14 Beats $0.04 Estimate, Sales $85.239M Beat $60.775M Estimate
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.04 by 250 percent. This is a 1300 percent increase over earnings of $0.01 per share
08-07 19:20
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Ironwood Pharmaceuticals (NASDAQ:IRWD) stock rose 15.2% to $0.71 durin...
06-14 05:05
美股大行评级 | 潜在涨幅684.71%！Verve Therapeutics获Canaccord Genuity升目标价至39美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119185980869894144.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Verve Therapeutics(VERV)"买入"评级，目标价从32美元升至39美元</p> <p>• HC Wainwright & Co.：维持Verve Ther
04-16 09:45
Trump targets Medicare price negotiations in new executive order
President Donald Trump on Tuesday signed an executive order to lower prescription drug prices through a series of measures, including a requirement to change a key provision in the Medicare drug price...
04-16 08:23
